3,6-Dioxabicyclo[6.2.2]dodeca-1(10),8,11-triene-2,7-dione;oxirane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,6-Dioxabicyclo[6.2.2]dodeca-1(10),8,11-triene-2,7-dione;oxirane
• 英文别名: 3,6-dioxabicyclo[6.2.2]dodeca-1(10),8,11-triene-2,7-dione;oxirane
• 化学式: C12H12O5
• 分子量: 236.22
• InChiKey: JZNJGNZEVUNASZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.03
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] DRUG DOSAGE FORMS FOR STOMACH RETENTION<br/>[FR] FORMES POSOLOGIQUES DE MÉDICAMENT À RETENUE DANS L'ESTOMAC
  申请人：[en]TRIASTEK, INC.

  公开号：WO2022089631A1

  公开（公告）日：2022-05-05

  Provided herein are drug dosage forms having a swellable component, which alone or in conjugation with one or more other components of the drug dosage forms expand the overall size of the drug dosage form in the stomach. The drug dosage forms are configured to be retained in the stomach for an extended period of time based on this increase in size of the drug dosage form in the stomach (e.g., retained in the stomach for a period of at least about 24 hours). The drug dosage forms described herein are formulated to release a drug during at least a portion of the stomach residency period. In other aspects, also provided are methods of designing, methods of making, such as using three-dimensional printing, and methods of delivering a drug to an individual, wherein such methods are associated with the drug dosage forms described herein.